Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
- PMID: 15026789
- PMCID: PMC2409664
- DOI: 10.1038/sj.bjc.6601700
Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
Abstract
The recommended phase II dose of paclitaxel 180 mg m(-2) given as a 3-h infusion followed by nedaplatin 100 mg m(-2) in a 1-h infusion every 3-4 weeks was determined in 52 chemo-naive patients with unresectable squamous cell carcinoma (SCC), with a promising response rate for lung SCC of 55%.
References
-
- Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86: 1086–1091 - PubMed
-
- Akiyama Y, Ohe Y, Tamura T, Sawada M, Inoue A, Kusaba H, Yamamoto N, Sekine I, Kunitoh H, Kodama T, Saijo N (2001) A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 31: 482–487 - PubMed
-
- Armitage P, Berry G (1994) Survival analysis. In Statistical Methods in Medical Research, Armitage P, Berry G (eds) 3rd edn, pp 469–492. Oxford: Blackwell Scientific Publications
-
- DeVita Jr VT, Hellman S, Rosenberg SA (2001) Cancer: Principles & Practice of Oncology, 6th edn Philadelphia: Lippincott Williams & Wilkins
-
- Forastiere AA, Shank D, Neuberg D, Taylor IV SG, DeConti RC, Adams G (1998) Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 82: 2270–2274 - PubMed